TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test a drug known as DFMO in people with Type 1
Diabetes (T1D). The main question[s] it aims to answer are:
- Does it reduce stress on the cells that make insulin?
- Does it preserve what is left of the body's insulin production? Participants will take
either DFMO or a placebo (looks like DFMO but has no active ingredients) two times a day
for about 6 months. Participants will have 6 in person visits and 1 phone visit over a
period of 12 months. Visits will include blood draws urine collection and other tests.
Phase:
Phase 2
Details
Lead Sponsor:
Emily K. Sims
Collaborators:
Cancer Prevention Pharmaceuticals, Inc. Juvenile Diabetes Research Foundation